Dual melanocortin‐4 receptor and GLP‐1 receptor agonism amplifies metabolic benefits in diet‐induced obese mice
Abstract We assessed the efficacy of simultaneous agonism at the glucagon‐like peptide‐1 receptor (GLP‐1R) and the melanocortin‐4 receptor (MC4R) for the treatment of obesity and diabetes in rodents. Diet‐induced obese (DIO) mice were chronically treated with either the long‐acting GLP‐1R agonist li...
Main Authors: | Christoffer Clemmensen, Brian Finan, Katrin Fischer, Robby Zachariah Tom, Beata Legutko, Laura Sehrer, Daniela Heine, Niklas Grassl, Carola W Meyer, Bart Henderson, Susanna M Hofmann, Matthias H Tschöp, Lex HT Van der Ploeg, Timo D Müller |
---|---|
Format: | Article |
Language: | English |
Published: |
Springer Nature
2015-02-01
|
Series: | EMBO Molecular Medicine |
Subjects: | |
Online Access: | https://doi.org/10.15252/emmm.201404508 |
Similar Items
-
Emerging role of GLP-1 receptor agonists in the treatment of obesity
by: Neff LM
Published: (2010-07-01) -
GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report
by: Eva W. Iepsen, et al.
Published: (2020-04-01) -
Liraglutide, a glucagon-like peptide-1 receptor agonist, ameliorates inflammation and apoptosis via inhibition of receptor for advanced glycation end products signaling in AGEs induced chondrocytes
by: Xianyu Zhang, et al.
Published: (2024-07-01) -
The GLP-1 agonist, liraglutide, ameliorates inflammation through the activation of the PKA/CREB pathway in a rat model of knee osteoarthritis
by: Qihong Que, et al.
Published: (2019-06-01) -
First GLP-1 analog liraglutide: the result of clinical trails on efficacy
by: Alexander Sergeevich Ametov, et al.
Published: (2011-12-01)